ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

zipalertinib

Also written as “TAS6417” and “CLN-081”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Lung Neoplasms · Carcinoma, led by 2 companies.

Drug pageZipalertinib: every studyAll 6 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jul 11, 20234 company-led studies, 4 open or runningNext primary completion: May 27, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Otsukaits history only33 open or runningphase 3since Jul 11, 2023Jul 11, 2023May 27, 2027phase 3 · NCT05973773
Cullinan Therapeutics11 open or runningphase 2since Jul 23, 2019Jul 23, 2019none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Cullinan Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jul 23, 2019First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT04036682 · 284 enrolled · United States, Hong Kong, Italy and more
  2. Jan 25, 2022Named zipalertinibINNProposed as its International Nonproprietary Name in WHO's List 126 · before, TAS6417, CLN-081

TargetBeta

EGFR →read by rule
“An orally available selective inhibitor of a broad spectrum of epidermal growth factor receptor (EGFR) mutations, including EGFR exon 20 insertion mutations (EGFR Ex20ins; Ex20ins mutations), ”NCIt, by rule
“Epidermal growth factor receptor erbB1 inhibitor”ChEMBL 37, by rule

Other programs on EGFR

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
pimurutamabFosun Pharmaphase 317
Anti-EGFR Antibody-drug Conjugate CPO301CSPC Pharmaceutical Groupphase 316
sunvozertinibruleDizal Pharmaceuticalsphase 312
becotatugCSPC Pharmaceutical Groupphase 311
andamertinibruleavistone-biotechnology-co-ltdphase 310
becotatug vedotinrulelepu-biopharma-co-ltdphase 310
sevabertinibruleBayerphase 38
HS-10504Hansoh Pharmaceutical Groupphase 37
befotertinibruleBetta Pharmaceuticalsphase 36
petosemtamabruleGenmabphase 36
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35

Studies

The one study Cullinan Therapeutics leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04036682Carcinoma, Non-Small-Cell Lung · United States, Hong Kong, Italy and more2Active, not recruitingOct 13, 2025284

How it is read

Names in the registry

  • “TAS6417”, 3 entries
  • “CLN-081”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.